143 related articles for article (PubMed ID: 25586473)
1. An overactive bladder online self-management program with embedded avatars: a randomized controlled trial of efficacy.
Andrade AD; Anam R; Karanam C; Downey P; Ruiz JG
Urology; 2015 Mar; 85(3):561-7. PubMed ID: 25586473
[TBL] [Abstract][Full Text] [Related]
2. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
3. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
4. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
[TBL] [Abstract][Full Text] [Related]
5. Effects of tolterodine ER on patient-reported outcomes in sexually active women with overactive bladder and urgency urinary incontinence.
Rogers RG; Bachmann G; Scarpero H; Jumadilova Z; Sun F; Morrow JD; Guan Z; Bavendam T
Curr Med Res Opin; 2009 Sep; 25(9):2159-65. PubMed ID: 19601704
[TBL] [Abstract][Full Text] [Related]
6. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.
Khullar V; Cardozo L; Kelleher CJ; Hall T; Ryan J; Ebel Bitoun C; Darekar A; Arumi D; Wagg A
BJU Int; 2013 Oct; 112(6):820-9. PubMed ID: 23465055
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
[TBL] [Abstract][Full Text] [Related]
8. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
[TBL] [Abstract][Full Text] [Related]
9. OnabotulinumtoxinA improves health-related quality of life in patients with urinary incontinence due to idiopathic overactive bladder: a 36-week, double-blind, placebo-controlled, randomized, dose-ranging trial.
Fowler CJ; Auerbach S; Ginsberg D; Hale D; Radziszewski P; Rechberger T; Patel VD; Zhou J; Thompson C; Kowalski JW
Eur Urol; 2012 Jul; 62(1):148-57. PubMed ID: 22464310
[TBL] [Abstract][Full Text] [Related]
10. Effects of an education program on toileting behaviors and bladder symptoms in overactive bladder patients with type 2 diabetes: A randomized clinical trial.
Xu D; Huang L; Gao J; Li J; Wang X; Wang K
Int J Nurs Stud; 2018 Nov; 87():131-139. PubMed ID: 30096579
[TBL] [Abstract][Full Text] [Related]
11. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
[TBL] [Abstract][Full Text] [Related]
13. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and tolerability of solifenacin in elderly subjects with overactive bladder syndrome: a pooled analysis.
Wagg A; Wyndaele JJ; Sieber P
Am J Geriatr Pharmacother; 2006 Mar; 4(1):14-24. PubMed ID: 16730617
[TBL] [Abstract][Full Text] [Related]
15. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
Wang AC; Chih SY; Chen MC
Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893
[TBL] [Abstract][Full Text] [Related]
16. A pelvic floor fitness program for older women with urinary symptoms: a feasibility study.
Dugan SA; Lavender MD; Hebert-Beirne J; Brubaker L
PM R; 2013 Aug; 5(8):672-6. PubMed ID: 23507346
[TBL] [Abstract][Full Text] [Related]
17. Impact of urinary incontinence on healthcare resource utilization, health-related quality of life and productivity in patients with overactive bladder.
Tang DH; Colayco DC; Khalaf KM; Piercy J; Patel V; Globe D; Ginsberg D
BJU Int; 2014 Mar; 113(3):484-91. PubMed ID: 24528881
[TBL] [Abstract][Full Text] [Related]
18. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
[TBL] [Abstract][Full Text] [Related]
19. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
[TBL] [Abstract][Full Text] [Related]
20. Solifenacin treatment for overactive bladder in Hispanic patients: patient-reported symptom bother and quality of life outcomes from the VESIcare Open-Label Trial.
Capo' JP; Laramée C; Lucente V; Fakhoury A; Forero-Schwanhaeuser S
Int J Clin Pract; 2008 Jan; 62(1):39-46. PubMed ID: 18036164
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
